296 related articles for article (PubMed ID: 22354311)
1. Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles.
Clemens DL; Lee BY; Xue M; Thomas CR; Meng H; Ferris D; Nel AE; Zink JI; Horwitz MA
Antimicrob Agents Chemother; 2012 May; 56(5):2535-45. PubMed ID: 22354311
[TBL] [Abstract][Full Text] [Related]
2. pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice.
Hwang AA; Lee BY; Clemens DL; Dillon BJ; Zink JI; Horwitz MA
Small; 2015 Oct; 11(38):5066-78. PubMed ID: 26193431
[TBL] [Abstract][Full Text] [Related]
3. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against
Hakkimane SS; Shenoy VP; Gaonkar SL; Bairy I; Guru BR
Int J Nanomedicine; 2018; 13():4303-4318. PubMed ID: 30087562
[TBL] [Abstract][Full Text] [Related]
4. Lower cytotoxicity, high stability, and long-term antibacterial activity of a poly(methacrylic acid)/isoniazid/rifampin nanogel against multidrug-resistant intestinal Mycobacterium tuberculosis.
Chen T; Li Q; Guo L; Yu L; Li Z; Guo H; Li H; Zhao M; Chen L; Chen X; Zhong Q; Zhou L; Wu T
Mater Sci Eng C Mater Biol Appl; 2016 Jan; 58():659-65. PubMed ID: 26478357
[TBL] [Abstract][Full Text] [Related]
5. An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages.
de Faria TJ; Roman M; de Souza NM; De Vecchi R; de Assis JV; dos Santos AL; Bechtold IH; Winter N; Soares MJ; Silva LP; De Almeida MV; Báfica A
Antimicrob Agents Chemother; 2012 May; 56(5):2259-67. PubMed ID: 22330919
[TBL] [Abstract][Full Text] [Related]
6. A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy.
Zhu M; Wang H; Liu J; He H; Hua X; He Q; Zhang L; Ye X; Shi J
Biomaterials; 2011 Mar; 32(7):1986-95. PubMed ID: 21163519
[TBL] [Abstract][Full Text] [Related]
7. Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.
Tarn D; Ashley CE; Xue M; Carnes EC; Zink JI; Brinker CJ
Acc Chem Res; 2013 Mar; 46(3):792-801. PubMed ID: 23387478
[TBL] [Abstract][Full Text] [Related]
8. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs.
Xia T; Kovochich M; Liong M; Meng H; Kabehie S; George S; Zink JI; Nel AE
ACS Nano; 2009 Oct; 3(10):3273-86. PubMed ID: 19739605
[TBL] [Abstract][Full Text] [Related]
9. Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254.
Dhillon J; Mitchison DA
Antimicrob Agents Chemother; 1989 Aug; 33(8):1255-9. PubMed ID: 2802553
[TBL] [Abstract][Full Text] [Related]
10. Multimetallic Microparticles Increase the Potency of Rifampicin against Intracellular Mycobacterium tuberculosis.
Ellis T; Chiappi M; García-Trenco A; Al-Ejji M; Sarkar S; Georgiou TK; Shaffer MSP; Tetley TD; Schwander S; Ryan MP; Porter AE
ACS Nano; 2018 Jun; 12(6):5228-5240. PubMed ID: 29767993
[TBL] [Abstract][Full Text] [Related]
11. Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity.
Carneiro SP; Carvalho KV; de Oliveira Aguiar Soares RD; Carneiro CM; de Andrade MHG; Duarte RS; Dos Santos ODH
Colloids Surf B Biointerfaces; 2019 Mar; 175():306-313. PubMed ID: 30553206
[TBL] [Abstract][Full Text] [Related]
12. Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and in Vitro Efficacy for Rifampicin and SQ641.
D'Addio SM; Reddy VM; Liu Y; Sinko PJ; Einck L; Prud'homme RK
Mol Pharm; 2015 May; 12(5):1554-63. PubMed ID: 25811733
[TBL] [Abstract][Full Text] [Related]
13. Mesoporous Silica Nanoparticles with pH-Sensitive Nanovalves for Delivery of Moxifloxacin Provide Improved Treatment of Lethal Pneumonic Tularemia.
Li Z; Clemens DL; Lee BY; Dillon BJ; Horwitz MA; Zink JI
ACS Nano; 2015 Nov; 9(11):10778-89. PubMed ID: 26435204
[TBL] [Abstract][Full Text] [Related]
14. Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages.
Choi SR; Britigan BE; Moran DM; Narayanasamy P
PLoS One; 2017; 12(5):e0177987. PubMed ID: 28542623
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Das Gupta U; Gupta P; Rath G; Goyal AK
Artif Cells Nanomed Biotechnol; 2016; 44(1):182-7. PubMed ID: 24992699
[TBL] [Abstract][Full Text] [Related]
16. The Effects Study of Isoniazid Conjugated Multi-Wall Carbon Nanotubes Nanofluid on
Zomorodbakhsh S; Abbasian Y; Naghinejad M; Sheikhpour M
Int J Nanomedicine; 2020; 15():5901-5909. PubMed ID: 32884258
[TBL] [Abstract][Full Text] [Related]
17. Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis.
Campos Pacheco JE; Yalovenko T; Riaz A; Kotov N; Davids C; Persson A; Falkman P; Feiler A; Godaly G; Johnson CM; Ekström M; Pilkington GA; Valetti S
J Control Release; 2024 May; 369():231-250. PubMed ID: 38479444
[TBL] [Abstract][Full Text] [Related]
18. Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages.
Yunus Basha R; T S SK; Doble M
Carbohydr Polym; 2019 Aug; 218():53-62. PubMed ID: 31221343
[TBL] [Abstract][Full Text] [Related]
19. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
20. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis.
Saraogi GK; Sharma B; Joshi B; Gupta P; Gupta UD; Jain NK; Agrawal GP
J Drug Target; 2011 Apr; 19(3):219-27. PubMed ID: 20540651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
